Samyang Biopharmaceuticals Corporation
Clinical trials sponsored by Samyang Biopharmaceuticals Corporation, explained in plain language.
South Korean pharmaceutical company focused on biologics and specialty drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New device aims to smooth away smile lines in quick trial Results expected Dec 2026 (estimated)
- New filler aims to smooth deep wrinkles Results expected Mar 2027 (estimated)
-
New filler aims to smooth deep wrinkles
Symptom relief Recruiting nowThis study tests a new injectable called DMFI300 for treating nasolabial folds (the lines from nose to mouth corners). Thirty adults will receive DMFI300 on one side of the face and a comparator filler on the other. Researchers will check wrinkle severity and safety over 12 month…
Sponsor: Samyang Biopharmaceuticals Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
New device aims to smooth away smile lines in quick trial
Symptom relief Recruiting nowThis study tests a device called DMFI150 to see if it can safely reduce the deep wrinkles from nose to mouth (nasolabial folds). 30 adults aged 18-70 with moderate to severe wrinkles will get one treatment. Doctors will check wrinkle improvement and safety for up to 12 months.
Sponsor: Samyang Biopharmaceuticals Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC